NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.70 0.00 (0.00 %) (As of 05/22/2019 06:54 AM ET)Previous Close$0.7048Today's Range$0.6733 - $0.714052-Week Range$0.49 - $3.59Volume1.40 million shsAverage Volume6.06 million shsMarket Capitalization$112.52 millionP/E RatioN/ADividend YieldN/ABeta1.21 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody for the treatment of squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts. Receive AVEO News and Ratings via Email Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AVEO Previous Symbol CUSIP05358810 CIK1325879 Webhttp://www.aveooncology.com/ Phone617-588-1960Debt Debt-to-Equity RatioN/A Current Ratio1.39 Quick Ratio1.54Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.41 million Price / Sales20.80 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-5.83Profitability EPS (Most Recent Fiscal Year)($0.19) Net Income$-5,330,000.00 Net Margins70.30% Return on Equity-24.50% Return on Assets38.75%Miscellaneous Employees17 Outstanding Shares160,739,000Market Cap$112.52 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions What is AVEO Pharmaceuticals' stock symbol? AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO." How were AVEO Pharmaceuticals' earnings last quarter? AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) posted its quarterly earnings results on Thursday, March, 14th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.03. The biopharmaceutical company earned $1.48 million during the quarter, compared to analyst estimates of $2.48 million. AVEO Pharmaceuticals had a net margin of 70.30% and a negative return on equity of 24.50%. View AVEO Pharmaceuticals' Earnings History. When is AVEO Pharmaceuticals' next earnings date? AVEO Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for AVEO Pharmaceuticals. What price target have analysts set for AVEO? 6 equities research analysts have issued 12-month price objectives for AVEO Pharmaceuticals' stock. Their forecasts range from $1.00 to $3.00. On average, they expect AVEO Pharmaceuticals' stock price to reach $2.20 in the next year. This suggests a possible upside of 214.3% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals. What is the consensus analysts' recommendation for AVEO Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AVEO Pharmaceuticals. What are Wall Street analysts saying about AVEO Pharmaceuticals stock? Here are some recent quotes from research analysts about AVEO Pharmaceuticals stock: 1. According to Zacks Investment Research, "AVEO missed on both earnings and revenues in the first quarter of 2019. The company got a huge boost from the approval for Fotivda in Europe regarding the first-line treatment of advanced renal cell carcinoma (RCC).However, AVEO faced a major setback when it had to delay its submission of a new drug application (NDA) for Fotivda in the United States. The company intended to submit the NDA in the first half of 2019 but now interim data will be available during the fourth quarter of 2019, subject to mature OS results. Although, the target market is lucrative, dependence on partners for pipeline development and funds accumulation is a concern. Failure to receive regulatory approvals or the termination of a deal would hamper AVEO’s future prospects. AVEO receives royalties from Fotivda sales in certain European countries. This is a key revenue driver. Shares of the company have underperformed the industry so far this year." (5/15/2019) 2. HC Wainwright analysts commented, "We maintain our Neutral rating on AVEO and our 12-month price target of $1.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected tivozanib and ficlatuzumab revenues through 2030 assuming a 12.0% discount rate and a 0% terminal growth rate. We derive an rNPV of $231M for the products and add in pro forma net cash and cash equivalents of $12.9M to arrive at a 12-month price target of $1.01 per diluted share, which we round to $1.00. (1) clinical; (2) commercial; (3) financial; (4) partnership; and (5) intellectual property." (3/18/2019) Has AVEO Pharmaceuticals been receiving favorable news coverage? News articles about AVEO stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AVEO Pharmaceuticals earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. Are investors shorting AVEO Pharmaceuticals? AVEO Pharmaceuticals saw a decline in short interest in the month of April. As of April 30th, there was short interest totalling 22,322,892 shares, a decline of 16.7% from the April 15th total of 26,786,866 shares. Based on an average trading volume of 3,584,000 shares, the short-interest ratio is currently 6.2 days. Approximately 16.7% of the company's shares are sold short. View AVEO Pharmaceuticals' Current Options Chain. Who are some of AVEO Pharmaceuticals' key competitors? Some companies that are related to AVEO Pharmaceuticals include Evolus (EOLS), INDIVIOR PLC/S (INVVY), Albireo Pharma (ALBO), Dynavax Technologies (DVAX), DiaMedica Therapeutics (DMCAF), Arcus Biosciences (RCUS), Savara (SVRA), Vital Therapies (VTL), Achillion Pharmaceuticals (ACHN), Cyclerion Therapeutics (CYCN), Kalvista Pharmaceuticals (KALV), Collegium Pharmaceutical (COLL), BioDelivery Sciences International (BDSI), Catalyst Pharmaceuticals (CPRX) and Progenics Pharmaceuticals (PGNX). What other stocks do shareholders of AVEO Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Check Cap (CHEK), Synergy Pharmaceuticals (SGYP), Denbury Resources (DNR), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX), Opko Health (OPK), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Portola Pharmaceuticals (PTLA). Who are AVEO Pharmaceuticals' key executives? AVEO Pharmaceuticals' management team includes the folowing people: Mr. Michael P. Bailey, CEO, Pres & Director (Age 54)Ms. Karuna Rubin, Sr. VP & Gen. Counsel (Age 42)Dr. Michael N. Needle, Chief Medical Officer (Age 59)Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 60)Dr. Emile Farhan Ph.D., VP of Technical Operations Who are AVEO Pharmaceuticals' major shareholders? AVEO Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.48%), BlueMountain Capital Management LLC (0.17%), Virtu Financial LLC (0.10%), State of Wisconsin Investment Board (0.09%), WealthTrust Axiom LLC (0.09%) and Morgan Stanley (0.07%). Company insiders that own AVEO Pharmaceuticals stock include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals. Which institutional investors are selling AVEO Pharmaceuticals stock? AVEO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Morgan Stanley and BlackRock Inc.. View Insider Buying and Selling for AVEO Pharmaceuticals. Which institutional investors are buying AVEO Pharmaceuticals stock? AVEO stock was bought by a variety of institutional investors in the last quarter, including BlueMountain Capital Management LLC, WealthTrust Axiom LLC, Virtu Financial LLC, SG Americas Securities LLC, Excalibur Management Corp, HCR Wealth Advisors and State of Wisconsin Investment Board. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Anthony B Evnin, Equity Opportunities Fu Growth, Equity Opportunities Iv Growth, Peter J Barris, Peter W Sonsini and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals. How do I buy shares of AVEO Pharmaceuticals? Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AVEO Pharmaceuticals' stock price today? One share of AVEO stock can currently be purchased for approximately $0.70. How big of a company is AVEO Pharmaceuticals? AVEO Pharmaceuticals has a market capitalization of $112.52 million and generates $5.41 million in revenue each year. The biopharmaceutical company earns $-5,330,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. AVEO Pharmaceuticals employs 17 workers across the globe. What is AVEO Pharmaceuticals' official website? The official website for AVEO Pharmaceuticals is http://www.aveooncology.com/. How can I contact AVEO Pharmaceuticals? AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected] MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 317 (Vote Outperform)Underperform Votes: 314 (Vote Underperform)Total Votes: 631MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Return On Assets Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.